Physician profile
Andrew Tucker
NPI 1831162767
$991.16
in general payments reported to CMS, 2019-2025
16 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.47 · 2021: $68.40 · 2023: $130 · 2024: $392 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $340.84 | 2024-2025 | Myfembree |
| Astellas Pharma US INC | $196.87 | 2023-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $65.31 | 2023-2024 | Aptima |
| Pfizer INC. | $58.27 | 2023-2025 | |
| Amag Pharmaceuticals, INC. | $52.47 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.16 | 2021-2025 | |
| Millicent US INC | $41.61 | 2025 | Femlyv |
| Exeltis, USA INC. | $41.23 | 2024-2025 | Slynd |
| Minerva Surgical, INC | $26.08 | 2025 | |
| Organon LLC | $22.28 | 2023 | Nexplanon |
| Myovant Sciences INC. | $20.75 | 2021 | |
| Alydia Health | $20.36 | 2021 | |
| Lsi Solutions INC | $15.81 | 2023 | Fornisee |
| Davol INC. | $15.71 | 2024 | |
| Aspira Women'S Health INC | $15.43 | 2024 | Ova1 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $12.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.